Janus Henderson Group PLC lifted its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 10.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,286 shares of the medical instruments supplier's stock after purchasing an additional 8,092 shares during the period. Janus Henderson Group PLC owned about 1.59% of Mesa Laboratories worth $11,379,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. raised its holdings in Mesa Laboratories by 4.3% in the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock valued at $231,000 after acquiring an additional 73 shares in the last quarter. Berry Wealth Group LP raised its holdings in shares of Mesa Laboratories by 5.3% in the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock valued at $219,000 after purchasing an additional 83 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Mesa Laboratories by 3.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier's stock worth $448,000 after purchasing an additional 100 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Mesa Laboratories by 2.6% during the fourth quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock worth $736,000 after purchasing an additional 141 shares in the last quarter. Finally, Amundi increased its holdings in Mesa Laboratories by 81.6% in the fourth quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after buying an additional 297 shares during the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.
Mesa Laboratories Stock Down 2.7%
NASDAQ MLAB traded down $3.23 during trading on Tuesday, reaching $115.32. 49,544 shares of the company's stock were exchanged, compared to its average volume of 39,898. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $155.12. The stock has a market cap of $626.65 million, a P/E ratio of -2.49 and a beta of 0.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. The company has a 50 day moving average price of $118.23 and a two-hundred day moving average price of $126.83.
Mesa Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's payout ratio is currently -1.38%.
Insider Activity at Mesa Laboratories
In other news, CEO Gary M. Owens sold 21,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now directly owns 43,337 shares in the company, valued at approximately $5,369,887.67. This trade represents a 32.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.40% of the company's stock.
About Mesa Laboratories
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Stories
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
